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Generalized junctional epidermolysis
bullosa (JEB) is caused by mutations in
LAMA3, LAMB3, or LAMC2, which
together encode laminin-332, a hetero-
trimeric protein consisting of a3, b3, and
g2 chains (Fine et al., 2014). In nonlethal
generalized intermediate JEB, laminin-
332 is highly reduced, and hemi-
desmosomes are rudimentary or
completely absent, leading to blister for-
mation within the lamina lucida of the
basementmembrane uponminor trauma.
The resulting chronic skin wounds
invariably develop recurrent infections
and scarring, which greatly impair pa-
tients’ quality of life (Fine et al., 2014;
Laimer et al., 2010; Nakano et al., 2002).There is no cure for JEB; treatments are
symptomatic and aimed at relieving the
devastating clinical manifestations
(Carulli et al., 2013). The only published
evidence for the possibility of a perma-
nent local treatment of JEB was provided
by a phase I/II trial showing that autolo-
gous epidermal cultures containing
geneticallymodified epidermal stem cells
were able to restore a normal epidermis
on a JEB patient (De Rosa et al., 2014;
Mavilio et al., 2006). However, the trans-
genic epidermis was applied in areas still
covered by a diseased but apparently
functional epidermis, which was surgi-
cally removed before grafting (Mavilio
et al., 2006). Although it is clear that the
ideal clinical application of transgenicepidermis would aim at preventing the
development of devastating chronic
lesions,manypatients suffer from therapy-
resistant chronic ulcerations that are
highly predisposed to cancer develop-
ment and need timely closure (Goldberg
et al., 1988; Hoste et al., 2015). We
report on a patient in whom gene-
corrected epidermal sheets were trans-
planted onto a large nonhealing
epidermal ulceration following a good
manufacturing practice protocol. This
single-case study was authorized by the
Austrian Ministry of Health, and all
experiments were approved by the Uni-
versity Hospital of the Paracelsus Medical
University, Salzburg. Written informed
consent was given by the patient, who
also consented on the publication of
photographs and medical information.
A 49-year-old woman with gener-
alized intermediate, laminin-332-
b3edependent JEB presented with a
large (approximately 80-cm2) wound
on her lower right leg (Figure 1a)
Figure 1. Regeneration of a transgenic functional epidermis on the skin wound of the JEB patient. (a)
The long-standing ulceration on the lower right leg of the patient 2 days before transplantation. (b)
Western blot analysis of cell lysates (20 mg protein, 30 seconds exposure time) from (lane 1) normal
control and patient keratinocyte cultures (lane 2) before and (lane 3) after gene correction, probed with a
monoclonal antibody against laminin 332-b3. (lane 4) Western blot analysis of a higher amount of loaded
protein (65 mg, 5 seconds exposure time) of uncorrected patient keratinocytes, and (lane 5) normal
keratinocyte cultures using the same laminin-332-b3 antibody. The 75-kD band in lane 4 is consistent
with the truncated laminin-332-b3 generated by the c.1903C>T; p.R635X mutation. (c) Transplantation
of cultured transgenic epidermal sheets (asterisks) on the prepared wound bed. Grafts are overlaid with
petrolatum gauze. (d) Initial epidermal regeneration at 14 days. (e) Complete epidermal regeneration at
3.5 months. (f) Stable epidermal regeneration at 16 months. Note crusting and erosions outside of the
grafted area. JEB, junctional epidermolysis bullosa.
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recurrent blisters covering her body
have been treated with conventional
therapies with varying success, the
large lesion on her right leg persisted
for over 10 years, and recurrent
infections led at one point to post-
streptococcal glomerulonephritis. In
July 2014 her ulceration was treated
with a combined ex vivo gene- and
autologous cell-therapy approach.
Primary patient keratinocytes,
obtained from a biopsy of the palm,
were transduced by the same retro-
viral vector (RV) expressing the full-
length LAMB3 cDNA under the
control of the Moloney leukemia virus
(MLV) long-terminal repeat, as used in
the previous study (Mavilio et al.,
2006), at an efficiency of 99.4% and
an average of two proviral copies per
cell (see Supplementary Figure S1
online). Whereas untransduced
patient keratinocytes contained barely
detectable amounts of laminin-332-b3
(Figure 1b, lanes 2 and 4), genetically
modified cells contained an amount
of laminin-332-b3 (Figure 1b, lane 3)
even higher than normal keratinocytes
(Figure 1b, lane 1). Transgene
expression persisted at constant levels
throughout the lifespan of the culture
(approximately 100 cell doublings,
data not shown).
Gene-corrected clonogenic cells
(w4  105) were expanded and used togrow two cohesive epidermal sheets of
approximately 80 cm2 to be transplanted
onto the leg ulceration after wound bed
preparation (Figure 1c). Complete
engraftment of the transgenic epidermis
was observed after 14 days (Figure 1d).
The skin was apparently normal, with
some hyperkeratosis originating from the
initial biopsy site, the lateral aspect of the
left palm. The graft remained mechani-
cally stable throughout the entire follow-
upperiod (16months) andwithout blister
formation, even upon shear force by
repeated rubbing of the skin (Figure 1e
and f).
On histological analysis of skin
biopsy samples taken at 1-year follow-
up, we observed a normal and fully
differentiated epidermis and a normal
dermal-epidermal junction (Figure 2b).
Immunofluorescence analysis showed
that the transgenic epidermis
expressed a normal amount of
laminin-332 (Figure 2c), comparable
to that observed in a normal control
(Figure 2d), that is properly located at
the dermal-epidermal junction. Trans-
mission electron microscopy showed
appropriate morphology of the base-
ment membrane zone in the trans-
planted area (Figure 2e), unlike the
patient’s lesional skin before grafting
(Figure 2f). In situ hybridization per-
formed using vector-specific LAMB3
probes showed homogenous expres-
sion of LAMB3 mRNA in all epidermallayers (Figure 2g), confirming that the
regenerated epidermis consists only of
transgenic keratinocytes. Because hu-
man epidermis is renewed monthly,
the patient’s transgenic epidermis un-
derwent at least 16 complete renewal
cycles during the 16 months of follow-
up. Thus, the long-term maintenance
of the regenerated epidermis must be
due to the engraftment of self-
renewing transduced epidermal stem
cells. This assumption was confirmed
by genome-wide analysis of RV inte-
gration sites performed on DNA
extracted from a 3-mm2 punch biopsy
sample of the transgenic epidermis at
1-year follow-up. Libraries of vector-
genome junctions, generated by
ligation-mediated nested PCR and
sequenced to saturation, retrieved
three independent integrations into
genes unambiguously mapped on the
human genome (see Supplementary
Table S1 online). Quantitative real-
time reverse transcriptaseePCR anal-
ysis performed on untransduced and
transduced primary cultures showed
no change in the expression of the
three genes, indicating that they were
not dysregulated through the proviral
integration (data not shown). Given an
average integration per cell of
1.5e2.0, as determined by Southern
blot analysis and previously shown
(Mavilio et al., 2006), these results
indicate that the w150 clonogenic
cells present in the small area of the
taken biopsy arise from at least two
single stem cell clones. These data
confirm the notion that the entire
regenerated epidermis is sustained
only by the engrafted stem cells (De
Rosa et al., 2014).
To ensure the safety of our
approach, we further demonstrated
the complete absence of pathogenic
antibodies against the newly syn-
thesized laminin-332-b3 protein
by indirect immunofluorescence
analysis using the patient’s plasma
collected 12 months after trans-
plantation (see Supplementary
Figure S2 online).
Despite the occurrence of severe
adverse events in patients with genetic
immunodeficiency treated with MLV-
based RV-transduced hematopoietic
stem cells (Carulli et al., 2013), these
vectors cannot per se be considered
oncogenic, because other clinical trialswww.jidonline.org 779
Figure 2. Expression of laminin-332 protein and LAMB3mRNA in the regenerated transgenic epidermis
and restoration of a normal dermal-epidermal junction. (a) Sections (7 mm thick) from the patient’s skin
before transplantation were immunostained using a polyclonal antibody against laminin-332. (b)
Hematoxylin and eosin staining of a skin section from a biopsy sample at 1-year follow-up. (c)
Immunofluorescence staining of laminin-332 in corrected skin after 1 year and (d) normal control skin
sections. Scale bars ¼ 10 mm. (e) Transmission electron microscopy performed on skin biopsy samples
from the transplanted area of the patient’s leg and (f) from the patient’s skin before transplantation.
Arrowheads indicate basement membrane; arrows show hemidesmosomes. Scale bars ¼ 0.5 mm. In situ
hybridization of LAMB3 mRNA using vector-specific LAMB3 probes was performed (g) in skin sections
taken from the transplanted area of the patient’s leg at the 1-year follow-up and (h) in sections of normal
control skin. Cell nuclei were counterstained with DAPI (blue). Dotted line shows dermal-epidermal
junction. Scale bars ¼ 20 mm.
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780using the same vector backbone in the
same cell type have not been accom-
panied by any serious adverse effects
(Aiuti et al., 2009). The safety of using
an MLV-based RV for skin gene therapy
approaches is underscored by the factJournal of Investigative Dermatology (2017), Volumthat during the 10 years’ follow-up of
the previously treated JEB patient, the
vector did not cause any adverse events
(De Rosa et al., 2014). This notion in-
dicates that the risk of vector-induced
mutagenesis might require othere 137factors possibly related to cell type,
genetic background, disease, and the
clinical protocol.
Taken together, our data show that
a functional epidermis has been
regenerated on a previously infected
nonhealing skin ulceration by a discrete
number of gene-corrected epidermal
stem cells, which might also reduce the
risk of cancer development in such
treated wounds. This underscores the
high therapeutic potential of ex vivo
gene therapy in the skin. On the basis of
these results, further affected skin areas
of the patient in this study can be
treated, and the technology can be
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